Zhongchao announced that Shanghai Zhongxin Medical, of which Zhongchao consolidates the operations and financial results through a series of contractual arrangements, has entered into a service agreement with Beijing Public Health Foundation, a non-profit organization dedicated to enhancing Chinese citizens’ health through public welfare initiatives and aid programs, to work together to develop a patient aid project. This Project will donate Trilaciclib Hydrochloride, which is used for protecting bone marrow during chemotherapy, to low-income cancer patients undergoing chemotherapy based on the patient’s needs. It aims to provide drug aids for bone marrow protection to mitigate chemotherapy-related adverse reactions and improve the safety of chemotherapy. Zhongxin, leveraging its self-developed patient assistance program technical service platform, is responsible for developing the information system for the Project, verifying patients’ medical and economic conditions, recruiting qualified patients, managing drug circulation, addressing patients’ related questions, and providing other supports. Zhongchao believes that this cooperation and the Project will address chemotherapy-related bone marrow suppression for target patients and alleviate their financial burden.
Published first on TheFly
